DNA X, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
SONM$2.35+5.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – At December 31, 2024 and 2023
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2024 and 2023
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | $5,343 | $9,397 |
| Accounts receivable, net | 4,339 | 25,304 |
| Non-trade receivable | 7,119 | 961 |
| Related party receivable | 181 | — |
| Inventory | 10,621 | 6,517 |
| Prepaid expenses and other current assets | 4,562 | 1,608 |
| Total current assets | 32,165 | 43,787 |
| Property and equipment, net | 227 | 71 |
| Contract fulfillment assets | 6,399 | 9,232 |
| Other assets | 948 | 2,953 |
| Total assets | $39,739 | $56,043 |
| Liabilities and stockholders’ equity | ||
| Accounts payable | $22,848 | $19,847 |
| Accrued liabilities | 20,892 | 12,300 |
| Total current liabilities | 43,740 | 32,147 |
| Income tax payable | 1,699 | 1,528 |
| Total liabilities | 45,439 | 33,675 |
| Commitments and contingencies (Note 10) | - | - |
| Stockholders’ equity (deficit) | ||
| Common stock, $0.001 par value per share; 100,000,000 shares authorized: and 4,983,868 and 4,426,867 shares issued and outstanding at December 31, 2024 and 2023, respectively* | 5 | 4 |
| Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Additional paid-in capital* | 277,903 | 272,324 |
| Accumulated deficit | (283,608) | (249,960) |
| Total stockholders’ equity (deficit) | (5,700) | 22,368 |
| Total liabilities and stockholders’ equity (deficit) | $39,739 | $56,043 |
| * | Adjusted retroactively to reflect the 1-for-10 reverse stock split that became effective on July 17, 2024, see Note 1. |
|---|
The accompanying notes are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.